Loading...

Jeffrey Bluestone, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentDiabetes Center
Phone415-514-0417
vCardDownload vCard
    Other Positions
    TitleProfessor, School of Medicine


    Collapse Biography 
    Collapse Education and Training
    Cornell Graduate School of Medical SciencePh.D.1980Immunology
    Rutgers - State UniversityM.S1977Microbiology
    Cook College, Rutgers UniversityB.S.1974Biology
    Collapse Awards and Honors
    Gould Foundation 1987  - 1989Faculty Scholar
    American Cancer Society1989Faculty Scholar
    Guggenheim Foundation1997Senior Fellowship
    Fogarty Foundation1997Senior Research Fellowship
    Cornell Medical School1998Distinguished Alumni Award
    Juvenile Diabetes Research Foundation2004Gerold & Kayla Grodsky Basic Science Award
    American Society for Transplantation2004Roche Distinguished Research Award
    Juvenile Diabetes Research Foundation2005Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award
    American Academy of Arts and Sciences2006Elected Member
    Juvenile Diabetes Research Foundation2008Scholar Award
    American Academy of Allergy, Asthma, & Immunology2010Elliott Middleton Memorial Lectureship
    National Academy of Medicine2013Elected Member
    American Society of Transplantation2015Outstanding Mentorship Award
    Federation of Clinical Immunology Societies2015President-Elect
    National Cancer Foundation2016Blue Ribbon Panel on Cancer Research (Biden Moonshot Program)

    Collapse Overview 
    Collapse Overview
    Jeffrey Bluestone, PhD, is the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and is the Director of the Hormone Research Institute in the Diabetes Center. His research over the past 25 years has focused on understanding the basic processes that control T cell activation and immune tolerance in autoimmunity and organ transplantation. He and members of his lab have developed soluble receptor antagonists; monoclonal antibodies and animals deficient in individual members of TCR and co-stimulatory pathways to define their individual roles in transplant rejection and autoimmunity including a special emphasis on a specialized subset of T cells termed “regulatory T cells” (Treg). Tregs control fundamental aspect of immune homeostasis. During the last several years, his research has adapted the animal studies using biologics and cell based therapies to develop therapeutics that can be used in humans with autoimmunity and under conditions of allotransplant rejection. Moreover, a strong role for antigen-specific Tregs have been found in these model systems and further evidence in humanized mice and transplant patients that alloantigen-specific Tregs are more effective. Thus, the major goal of this work is to identify the antigen-specificity of thymic- and peripherally-derived Tregs with the expectation that these TCRs can be adapted for immunotherapy. Finally, his lab initiated several projects to determine mechanisms that control Treg stability. The goal is to develop approaches using pharmacogenomics to either stabilize or destabilize Tregs in autoimmunity and cancer.

    In March 2010 Dr. Bluestone was appointed executive vice chancellor and provost at the University of California San Francisco (UCSF) serving as chief academic officer guiding the research and academic enterprise advancing the campus priorities in close collaboration with the chancellor and the campus leadership teams, and to oversee the campus ethics and compliance enterprise. Previously he served in a number of posts including Director of theUCSF Diabetes Center, as Director of the Immune Tolerance Network.

    In June 2008 Dr. Bluestone served as interim vice chancellor of research; directing the advancement of cross-campus research initiatives, such as enhancing core research facilities. In this capacity, he played a leading role in coordinating and integrating current research cores. He worked also to strengthen external research partnerships, particularly with industry, and focused on facilitating the translation of UCSF discoveries into public benefit.

    In 2009, Dr. Bluestone led the UCSF committee to strategize and secure funds available through the American Recovery and Reinvestment Act, making the campus one of the top institutional recipients in the nation of science-based stimulus funds.

    Dr. Bluestone joined the UCSF faculty in 2000. He is an international leader in the field of immunotherapy, with a stellar record of scholarly achievement and a decade of significant contributions to the research enterprise at UCSF, including the creation and directorship of an integrated UCSF Diabetes Center to focus on translating basic research in both type 1 and type 2 diabetes into improved therapies for patients. He also founded and directed the Immune Tolerance Network, a consortium of more than 1,000 of the world’s leading scientific researchers and clinical specialists from nearly 50 institutions, with the mission of testing new therapies to promote immune tolerance in transplantation, autoimmune diseases, asthma and allergic diseases.

    As a research scientist, Dr. Bluestone has helped clarify the body’s immune response on a molecular level. His systematic investigation has catalyzed recent progress in stem cell research, islet cell transplantation and immune tolerance therapies – experimentation that has formidably translated into drugs to treat human disease.

    Through his 30-year scientific career, he has authored more than 300 peer-reviewed publications that include prominent papers in Nature, Nature Immunology, and the Journal of Immunology and Diabetes. He has received numerous accolades for his work, including his 2006 election to the American Academy of Arts and Sciences, the Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation, and the distinguished alumni award from the Cornell Graduate School of Medical Science.

    Prior to joining UCSF, Bluestone was at the University of Chicago, where he was a member of the Ben May Institute for Cancer Research, rising over 13 years from an associate professor to the director of the institute. He had previously worked for seven years in various roles at the National Cancer Institute of the National Institutes of Health, ultimately becoming a senior investigator in the Immunology Branch of the National Cancer Institute.

    Dr. Bluestone earned both his BS in biology and his MS in microbiology from Rutgers State University, and his PhD in immunology from the Cornell Graduate School of Medical Science (Sloan-Kettering Division).


    Collapse Research 
    Collapse Research Activities and Funding
    Designer Tregs for restoring tolerance in patients with type 1 diabetes
    NIH/NIDDK UC4DK116264Sep 20, 2017 - Aug 31, 2021
    Role: Principal Investigator
    Using human stem cell-derived thymic epithelium to remodel T1D immune tolerance
    NIH/NIDDK R01DK107383Jul 1, 2016 - Jun 30, 2020
    Role: Co-Principal Investigator
    Using human stem cell-derived thymic epithelium to remodel T1D immune tolerance
    NIH/NIDDK U01DK107383Jul 1, 2016 - Jun 30, 2020
    Role: Co-Principal Investigator
    Disruption of T cell tolerance in type 1 diabetes
    NIH/NIAID P01AI118688Jun 8, 2016 - May 31, 2021
    Role: Co-Investigator
    Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation
    NIH/NIAID U01AI110658Jun 1, 2014 - May 31, 2019
    Role: Co-Principal Investigator
    Autoimmunity Center of Excellence Clinical Research Program
    NIH/NIAID UM1AI110498May 1, 2014 - Apr 30, 2019
    Role: Co-Investigator
    Role of Innate Lymphoid Cells in Autoimmunity
    NIH/NIAID R21AI107328Dec 1, 2013 - Nov 30, 2015
    Role: Principal Investigator
    "Donor-Specific Regulatory T Cell Therapy in Liver Transplantation"
    NIH/NIAID R34AI095135Apr 1, 2012 - Mar 31, 2014
    Role: Co-Principal Investigator
    "Expanding beta-cell mass"
    NIH/NIDDK U01DK089541Sep 15, 2010 - Jun 30, 2015
    Role: Co-Principal Investigator
    Role of Notch 1 in Immune Tolerance
    NIH/NIAID R21AI059979Apr 1, 2004 - Mar 31, 2007
    Role: Principal Investigator
    Autoimmunity Center of Excellence
    NIH/NIAID U19AI056388Sep 30, 2003 - Apr 30, 2014
    Role: Co-Investigator
    Diabetes Research Center
    NIH/NIDDK P30DK063720Sep 1, 2002 - Mar 31, 2020
    Role: Co-Principal Investigator
    Conf on Mechanism and Applications of Immune Tolerance
    NIH/NIAID R13AI051294Apr 1, 2002 - Mar 31, 2003
    Role: Principal Investigator
    Spontaneous Autoimmune Model of Peripheral Neuropathy
    NIH/NIAID R01AI050834Dec 15, 2001 - Nov 30, 2012
    Role: Principal Investigator
    Immune Tolerance Network: Autoimmune Diseases
    NIH/NIAID N01AI15416Sep 30, 2001 - Apr 30, 2014
    Role: Co-Principal Investigator
    Immune tolerance network: lung transplantation
    NIH/NIAID N01AI15416-20-0-10Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: liver transplantation
    NIH/NIAID N01AI15416-20-0-11Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Systemic lupus rythematosus (SLE)
    NIH/NIAID N01AI15416-20-0-12Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Kidney, Liver and Bone Marrow Transplantation
    NIH/NIAID N01AI15416-20-0-2Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Food Allergy
    NIH/NIAID N01AI15416-20-0-3Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Type 1 diabetes
    NIH/NIAID N01AI15416-20-0-4Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: Multiple sclerosis
    NIH/NIAID N01AI15416-20-0-5Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: Rheumatoid arthritis
    NIH/NIAID N01AI15416-20-0-6Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: Autoimmune diseases: Vasculitis
    NIH/NIAID N01AI15416-20-0-7Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: Islet cell transplantation
    NIH/NIAID N01AI15416-20-0-8Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: heart tranplantation
    NIH/NIAID N01AI15416-20-0-9Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: liver transplantation
    NIH N01AI15416-23-0-11Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Systemic lupus rythematosus (SLE)
    NIH N01AI15416-23-0-12Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: kidney transplantation
    NIH N01AI15416-23-0-13Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    IImmune Tolerance Network: Airborne Allergens and Allergic Rhintitis
    NIH N01AI15416-23-0-14Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Food Allergy
    NIH N01AI15416-23-0-3Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune Tolerance Network: Type 1 diabetes
    NIH N01AI15416-23-0-4Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    Immune tolerance network: Multiple sclerosis
    NIH N01AI15416-23-0-5Sep 30, 2001 - Apr 30, 2014
    Role: Principal Investigator
    FASEB SUMMER CONFERENCE--LYMPHOCYTES AND ANTIBODIES
    NIH/NIAID R13AI047114Jun 1, 2000 - May 31, 2001
    Role: Principal Investigator
    Immunomodulation of transplant rejection by Anti-CD3 mAb
    NIH/NIAID R01AI046643Mar 1, 2000 - May 31, 2016
    Role: Principal Investigator
    IMMUNOMODULATION OF TRANSPLANT REJECTION BY ANTI-CD3 MAB
    NIH/NIAID R37AI046643Mar 1, 2000 - Feb 28, 2011
    Role: Principal Investigator
    MOFLO MULTILASER FLOW CYTOMETER
    NIH/NCRR S10RR014884Mar 1, 2000 - Feb 28, 2001
    Role: Principal Investigator
    COLLABORATIVE NETWORK FOR CLINICAL RES ON IMMUNE TOLERAN
    NIH/NIAID N01AI095380Sep 30, 1999 - Sep 29, 2006
    Role: Principal Investigator
    TOLERANCE OF ISLET CELL GRAFT
    NIH/NIDDK R01DK055351Jun 15, 1999 - May 31, 2003
    Role: Principal Investigator
    CTLA 4 ANTAGONISM DURING T CELL ACTIVATION
    NIH/NIAID F33AI009895Mar 22, 1998
    Role: Principal Investigator
    SCOR in Cellular and Molecular Mechanisms of Asthma
    NIH/NHLBI P50HL056399Sep 30, 1996 - Aug 31, 2006
    Role: Co-Principal Investigator
    IMMUNOREGULATION OF IDDM
    NIH P01DK049799Jun 15, 1995 - May 31, 2000
    Role: Co-Investigator
    Immune Tolerance and Autoimmunity
    NIH/NIAID P01AI035297Sep 30, 1993 - Jul 31, 2012
    Role: Co-Investigator
    COSTIMULATION IN PERIPHERAL T CELL TOLERANCE AND ANERGY
    NIH/NIAID P01AI035294Sep 1, 1993 - Aug 31, 2001
    Role: Principal Investigator
    IMMUNOMODULATION OF TRANSPLANT REJECTION
    NIH/NIAID P01AI029531Jun 1, 1990 - Aug 31, 2000
    Role: Principal Investigator
    IMMUNOBIOLOGY OF TCR GAMMA/DELTA T-CELLS
    NIH/NIAID R01AI026847Sep 1, 1988 - Aug 31, 1999
    Role: Principal Investigator
    IN VIVO POTENTIATION OF IMMUNE RESPONSES
    NIH/NCI R01CA049260Aug 5, 1988 - Jul 31, 1995
    Role: Principal Investigator
    Interdisciplinary Training Program in Immunology
    NIH/NIAID T32AI007090Jul 1, 1979 - Jun 30, 2019
    Role: Co-Principal Investigator
    Cancer Center Support Grant
    NIH P30CA014599Feb 1, 1977 - Mar 31, 2018
    Role: Co-Investigator
    IMMUNITY AND CANCER
    NIH P01CA019266Jun 1, 1976 - Mar 31, 1996
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sneddon JB, Tang Q, Stock P, Bluestone J, Roy S, Desai T, Hebrok M. Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges. Cell Stem Cell. 2018 Jun 01; 22(6):810-823. PMID: 29859172.
      View in: PubMed
    2. Hua J, Inomata T, Chen Y, Foulsham W, Stevenson W, Shiang T, Bluestone J, Dana R. Pathological conversion of regulatory T cells is associated with loss of allotolerance. Sci Rep. 2018 May 04; 8(1):7059. PMID: 29728574.
      View in: PubMed
    3. Spence A, Purtha W, Tam J, Dong S, Kim Y, Ju CH, Sterling T, Nakayama M, Robinson WH, Bluestone J, Anderson MS, Tang Q. Revealing the specificity of regulatory T cells in murine autoimmune diabetes. Proc Natl Acad Sci U S A. 2018 May 15; 115(20):5265-5270. PMID: 29712852.
      View in: PubMed
    4. Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone J, Garcia KC. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018 03 02; 359(6379):1037-1042. PMID: 29496879.
      View in: PubMed
    5. Fuchs A, Gliwinski M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone J, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Golab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grzes D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Front Immunol. 2017; 8:1844. PMID: 29379498.
      View in: PubMed
    6. Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone J, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017 Nov; 18(11):e653-e706. PMID: 29208398.
      View in: PubMed
    7. Yeh WI, Seay HR, Newby B, Posgai AL, Moniz FB, Michels A, Mathews CE, Bluestone J, Brusko TM. Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes. Front Immunol. 2017; 8:1313. PMID: 29123516.
      View in: PubMed
    8. Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, Naddaf N, Chu JS, Ma H, Boyer E, Van Gool F, Huang H, Liu R, Tobin VR, Schumann K, Daly MJ, Farh KK, Ansel KM, Ye CJ, Greenleaf WJ, Anderson MS, Bluestone J, Chang HY, Corn JE, Marson A. Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature. 2017 09 07; 549(7670):111-115. PMID: 28854172.
      View in: PubMed
    9. June CH, Warshauer JT, Bluestone J. Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017 Aug 04; 23(8):1004. PMID: 28777789.
      View in: PubMed
    10. June CH, Warshauer JT, Bluestone J. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017 05 05; 23(5):540-547. PMID: 28475571.
      View in: PubMed
    11. Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone J, Papa FR. Targeting ABL-IRE1a Signaling Spares ER-Stressed Pancreatic ß Cells to Reverse Autoimmune Diabetes. Cell Metab. 2017 05 02; 25(5):1207. PMID: 28467938.
      View in: PubMed
    12. Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone J, Papa FR. Targeting ABL-IRE1a Signaling Spares ER-Stressed Pancreatic ß Cells to Reverse Autoimmune Diabetes. Cell Metab. 2017 Apr 04; 25(4):883-897.e8. PMID: 28380378.
      View in: PubMed
    13. Bluestone J. FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance. J Immunol. 2017 02 01; 198(3):979-980. PMID: 28115585.
      View in: PubMed
    14. Seay HR, Putnam AL, Cserny J, Posgai AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, Brown KS, Balavage KT, Peters LD, Bushdorf AN, Atkinson MA, Bluestone J, Haller MJ, Brusko TM. Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. Mol Ther Methods Clin Dev. 2017 Mar 17; 4:178-191. PMID: 28345003.
      View in: PubMed
    15. Esensten JH, Bluestone J, Lim WA. Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annu Rev Pathol. 2017 Jan 24; 12:305-330. PMID: 27959633.
      View in: PubMed
    16. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone J. CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016 05 17; 44(5):973-88. PMID: 27192564; PMCID: PMC4932896 [Available on 05/17/17].
    17. Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone J, Buckner JH, Ziegler SF. Correction: CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016 May 01; 196(9):3966. PMID: 27183651.
      View in: PubMed
    18. Gitelman SE, Bluestone J. Regulatory T cell therapy for type 1 diabetes: May the force be with you. J Autoimmun. 2016 07; 71:78-87. PMID: 27133597.
      View in: PubMed
    19. Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone J, Ehlers MR. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia. 2016 06; 59(6):1153-61. PMID: 27053235; PMCID: PMC4869699.
    20. DuPage M, Bluestone J. Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol. 2016 Mar; 16(3):149-63. PMID: 26875830.
      View in: PubMed
    21. Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone J, Buckner JH, Ziegler SF. CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016 Mar 01; 196(5):2051-2062. PMID: 26826243; PMCID: PMC4761490 [Available on 03/01/17].
    22. Perdigoto AL, Chatenoud L, Bluestone J, Herold KC. Inducing and Administering Tregs to Treat Human Disease. Front Immunol. 2015; 6:654. PMID: 26834735; PMCID: PMC4722090.
    23. Bluestone J, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015 Nov 25; 7(315):315ra189. PMID: 26606968.
      View in: PubMed
    24. Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone J, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, Turka LA, Utz JJ, Wang YM, Whitley CB, Kazi ZB, Pariser AR. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab. 2016 Feb; 117(2):66-83. PMID: 26597321.
      View in: PubMed
    25. Holohan DR, Lee JC, Bluestone J. Shifting the Evolving CAR T Cell Platform into Higher Gear. Cancer Cell. 2015 Oct 12; 28(4):401-402. PMID: 26461084.
      View in: PubMed
    26. Spence A, Klementowicz JE, Bluestone J, Tang Q. Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol. 2015 Dec; 37:11-20. PMID: 26432763.
      View in: PubMed
    27. Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone J, Doudna JA, Marson A. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. 2015 Aug 18; 112(33):10437-42. PMID: 26216948; PMCID: PMC4547290.
    28. Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone J, Locksley RM. Interleukin-33 and Interferon-? Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. Immunity. 2015 Jul 21; 43(1):161-74. PMID: 26092469; PMCID: PMC4512852.
    29. Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, Atkinson MA, Bluestone J, Brusko TM. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. J Immunol. 2015 Jul 01; 195(1):145-55. PMID: 25994968; PMCID: PMC4475416.
    30. Bluestone J, Crellin N, Trotta E. IL-2: Change Structure … Change Function. Immunity. 2015 May 19; 42(5):779-81. PMID: 25992850.
      View in: PubMed
    31. Bluestone J, Bour-Jordan H, Cheng M, Anderson M. T cells in the control of organ-specific autoimmunity. J Clin Invest. 2015 Jun; 125(6):2250-60. PMID: 25985270; PMCID: PMC4497750.
    32. Bluestone J, Trotta E, Xu D. The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opin Ther Targets. 2015; 19(8):1091-103. PMID: 25881491.
      View in: PubMed
    33. Bluestone J, Tang Q. Immunotherapy: making the case for precision medicine. Sci Transl Med. 2015 Mar 25; 7(280):280ed3. PMID: 25810308.
      View in: PubMed
    34. Villalta SA, Rosenberg AS, Bluestone J. The immune system in Duchenne muscular dystrophy: Friend or foe. Rare Dis. 2015; 3(1):e1010966. PMID: 26481612; PMCID: PMC4588155.
    35. DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, Turka L, Marson A, Bluestone J. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity. 2015 Feb 17; 42(2):227-238. PMID: 25680271; PMCID: PMC4347854.
    36. Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, Townamchai N, Gerriets VA, Rathmell JC, Sharpe AH, Bluestone J, Turka LA. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat Immunol. 2015 Feb; 16(2):188-96. PMID: 25559257; PMCID: PMC4297515.
    37. Xu P, Bailey-Bucktrout S, Xi Y, Xu D, Du D, Zhang Q, Xiang W, Liu J, Melton A, Sheppard D, Chapman HA, Bluestone J, Derynck R. Innate antiviral host defense attenuates TGF-ß function through IRF3-mediated suppression of Smad signaling. Mol Cell. 2014 Dec 18; 56(6):723-37. PMID: 25526531; PMCID: PMC4273650 [Available on 12/18/15].
    38. Szot GL, Yadav M, Lang J, Kroon E, Kerr J, Kadoya K, Brandon EP, Baetge EE, Bour-Jordan H, Bluestone J. Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell. 2015 Feb 05; 16(2):148-57. PMID: 25533131.
      View in: PubMed
    39. Van Gool F, Molofsky AB, Morar MM, Rosenzwajg M, Liang HE, Klatzmann D, Locksley RM, Bluestone J. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood. 2014 Dec 04; 124(24):3572-6. PMID: 25323825; PMCID: PMC4256909.
    40. Villalta SA, Rosenthal W, Martinez L, Kaur A, Sparwasser T, Tidball JG, Margeta M, Spencer MJ, Bluestone J. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med. 2014 Oct 15; 6(258):258ra142. PMID: 25320234; PMCID: PMC4889432.
    41. Folias AE, Penaranda C, Su AL, Bluestone J, Hebrok M. Aberrant innate immune activation following tissue injury impairs pancreatic regeneration. PLoS One. 2014; 9(7):e102125. PMID: 25010227; PMCID: PMC4092101.
    42. Stumpf M, Zhou X, Chikuma S, Bluestone J. Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol. 2014 Jun; 44(6):1737-46. PMID: 24648182; PMCID: PMC4051436.
    43. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone J, Takayanagi H. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014 Jan; 20(1):62-8. PMID: 24362934.
      View in: PubMed
    44. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone J. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity. 2013 Nov 14; 39(5):949-62. PMID: 24238343; PMCID: PMC3912996.
    45. Tang Q, Bluestone J. Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med. 2013 Nov 01; 3(11). PMID: 24186492.
      View in: PubMed
    46. Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone J, Ehlers MR. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):306-16. PMID: 24622416.
      View in: PubMed
    47. Yadav M, Stephan S, Bluestone J. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol. 2013; 4:232. PMID: 23966994; PMCID: PMC3736167.
    48. Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone J. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. J Exp Med. 2013 Jul 29; 210(8):1603-19. PMID: 23878307; PMCID: PMC3727315.
    49. Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M, Sonnenburg JL, Comstock LE, Bluestone J, Fischbach MA. Production of a-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol. 2013 Jul; 11(7):e1001610. PMID: 23874157; PMCID: PMC3712910.
    50. de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone J, Jeker LT. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol. 2013 Aug 15; 191(4):1594-605. PMID: 23858035; PMCID: PMC4160833.
    51. Bour-Jordan H, Thompson HL, Giampaolo JR, Davini D, Rosenthal W, Bluestone J. Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background. J Autoimmun. 2013 Sep; 45:58-67. PMID: 23850635; PMCID: PMC4156399.
    52. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone J. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov; 62(11):3766-74. PMID: 23835333.
      View in: PubMed
    53. Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone J. Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes. 2013 Aug; 62(8):2870-8. PMID: 23835340; PMCID: PMC3717875.
    54. Baumjohann D, Kageyama R, Clingan JM, Morar MM, Patel S, de Kouchkovsky D, Bannard O, Bluestone J, Matloubian M, Ansel KM, Jeker LT. The microRNA cluster miR-17~92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol. 2013 Aug; 14(8):840-8. PMID: 23812098; PMCID: PMC3720769.
    55. Jeker LT, Zhou X, Blelloch R, Bluestone J. DGCR8-mediated production of canonical microRNAs is critical for regulatory T cell function and stability. PLoS One. 2013; 8(5):e66282. PMID: 23741528; PMCID: PMC3669207.
    56. Jeker LT, Bluestone J. MicroRNA regulation of T-cell differentiation and function. Immunol Rev. 2013 May; 253(1):65-81. PMID: 23550639; PMCID: PMC3621017.
    57. Fischbach MA, Bluestone J, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013 Apr 03; 5(179):179ps7. PMID: 23552369; PMCID: PMC3772767.
    58. Herold KC, Vignali DA, Cooke A, Bluestone J. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013 Apr; 13(4):243-56. PMID: 23524461.
      View in: PubMed
    59. Abbas AK, Benoist C, Bluestone J, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013 Apr; 14(4):307-8. PMID: 23507634.
      View in: PubMed
    60. Huang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone J, Riley JL, Ziegler SF. Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28. J Immunol. 2013 May 01; 190(9):4470-3. PMID: 23543754; PMCID: PMC4197931.
    61. Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone J, Herold KC. Immune therapy and ß-cell death in type 1 diabetes. Diabetes. 2013 May; 62(5):1676-80. PMID: 23423576; PMCID: PMC3636605.
    62. Stumpf M, Zhou X, Bluestone J. The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. J Immunol. 2013 Feb 01; 190(3):961-9. PMID: 23293354; PMCID: PMC3568535.
    63. Bluestone J, Bour-Jordan H. Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol. 2012 Nov 01; 4(11). PMID: 23125012; PMCID: PMC3536337.
    64. Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone J, Kang SM, Peddi VR, Vincenti F. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int. 2012 Dec; 25(12):1257-67. PMID: 22994802.
      View in: PubMed
    65. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, Ruminski P, Weiss D, Von Schack D, Bluestone J. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med. 2012 Sep 24; 209(10):1713-22, S1-19. PMID: 22966003; PMCID: PMC3457729.
    66. Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone J, Kim J, Lee KM. Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers. Nano Lett. 2012 Aug 08; 12(8):4018-24. PMID: 22784189.
      View in: PubMed
    67. Bluestone J, Small EJ. The future of cancer treatment: will it include immunotherapy? Cancer Cell. 2012 Jul 10; 22(1):7-8. PMID: 22789534.
      View in: PubMed
    68. Penaranda C, Kuswanto W, Hofmann J, Kenefeck R, Narendran P, Walker LS, Bluestone J, Abbas AK, Dooms H. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):12668-73. PMID: 22733744; PMCID: PMC3411948.
    69. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone J, Buckner JH, Greenbaum CJ. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs ß-cell function. Diabetes. 2012 Sep; 61(9):2340-8. PMID: 22721971.
      View in: PubMed
    70. Jeker LT, Zhou X, Gershberg K, de Kouchkovsky D, Morar MM, Stadthagen G, Lund AH, Bluestone J. MicroRNA 10a marks regulatory T cells. PLoS One. 2012; 7(5):e36684. PMID: 22629323; PMCID: PMC3356350.
    71. Beilke JN, Meagher CT, Hosiawa K, Champsaur M, Bluestone J, Lanier LL. NK cells are not required for spontaneous autoimmune diabetes in NOD mice. PLoS One. 2012; 7(4):e36011. PMID: 22558306; PMCID: PMC3338490.
    72. Park CY, Jeker LT, Carver-Moore K, Oh A, Liu HJ, Cameron R, Richards H, Li Z, Adler D, Yoshinaga Y, Martinez M, Nefadov M, Abbas AK, Weiss A, Lanier LL, de Jong PJ, Bluestone J, Srivastava D, McManus MT. A resource for the conditional ablation of microRNAs in the mouse. Cell Rep. 2012 Apr 19; 1(4):385-91. PMID: 22570807.
      View in: PubMed
    73. Jeker LT, Bour-Jordan H, Bluestone J. Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a007807. PMID: 22393537; PMCID: PMC3282496.
    74. Tang Q, Bluestone J, Kang SM. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol. 2012 Feb; 4(1):11-21. PMID: 22170955; PMCID: PMC3695644.
    75. Bluestone J. The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med. 2011 Dec 01; 365(22):2129-31. PMID: 22129258.
      View in: PubMed
    76. Tada A, Shimada A, Yamada T, Oikawa Y, Yamada Y, Okubo Y, Irie J, Bluestone J, Itoh H. A mimic of viral double-stranded RNA triggers fulminant type 1 diabetes-like syndrome in regulatory T cell-deficient autoimmune diabetic mouse. J Immunol. 2011 Nov 15; 187(10):4947-53. PMID: 21967896.
      View in: PubMed
    77. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone J. Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413. J Immunol. 2011 Oct 01; 187(7):3466-74. PMID: 21934098.
      View in: PubMed
    78. Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, Schönfeld EA, Böttcher J, Golovina T, Mayer CT, Hofmann A, Sommer D, Debey-Pascher S, Endl E, Limmer A, Hippen KL, Blazar BR, Balderas R, Quast T, Waha A, Mayer G, Famulok M, Knolle PA, Wickenhauser C, Kolanus W, Schermer B, Bluestone J, Barry SC, Sparwasser T, Riley JL, Schultze JL. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol. 2011 Aug 14; 12(9):898-907. PMID: 21841785; PMCID: PMC3669688.
    79. Herold KC, Bluestone J. Type 1 diabetes immunotherapy: is the glass half empty or half full? Sci Transl Med. 2011 Aug 10; 3(95):95fs1. PMID: 21832236.
      View in: PubMed
    80. Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O'Connor W, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone J, Herold KC, Flavell RA. Control of TH17 cells occurs in the small intestine. Nature. 2011 Jul 17; 475(7357):514-8. PMID: 21765430; PMCID: PMC3148838.
    81. Penaranda C, Tang Q, Bluestone J. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol. 2011 Aug 15; 187(4):2015-22. PMID: 21742976; PMCID: PMC3150219.
    82. Bailey-Bucktrout SL, Bluestone J. Regulatory T cells: stability revisited. Trends Immunol. 2011 Jul; 32(7):301-6. PMID: 21620768; PMCID: PMC3129467.
    83. Rainbow DB, Moule C, Fraser HI, Clark J, Howlett SK, Burren O, Christensen M, Moody V, Steward CA, Mohammed JP, Fusakio ME, Masteller EL, Finger EB, Houchins JP, Naf D, Koentgen F, Ridgway WM, Todd JA, Bluestone J, Peterson LB, Mattner J, Wicker LS. Evidence that Cd101 is an autoimmune diabetes gene in nonobese diabetic mice. J Immunol. 2011 Jul 01; 187(1):325-36. PMID: 21613616.
      View in: PubMed
    84. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone J. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/?B7 family. Immunol Rev. 2011 May; 241(1):180-205. PMID: 21488898; PMCID: PMC3077803.
    85. Bluestone J. Mechanisms of tolerance. Immunol Rev. 2011 May; 241(1):5-19. PMID: 21488886.
      View in: PubMed
    86. Atkinson MA, Bluestone J, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ. How does type 1 diabetes develop?: the notion of homicide or ß-cell suicide revisited. Diabetes. 2011 May; 60(5):1370-9. PMID: 21525508; PMCID: PMC3292309.
    87. Brennan TV, Tang Q, Liu FC, Hoang V, Bi M, Bluestone J, Kang SM. Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts. J Surg Res. 2011 Jul; 169(1):e69-75. PMID: 21571317; PMCID: PMC3114634.
    88. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone J, Brusko TM. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011 Apr 01; 186(7):3918-26. PMID: 21368230; PMCID: PMC3091943.
    89. Nikoopour E, Sandrock C, Huszarik K, Krougly O, Lee-Chan E, Masteller EL, Bluestone J, Singh B. Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol. 2011 Apr 01; 186(7):3831-5. PMID: 21357258.
      View in: PubMed
    90. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone J, Riley JL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One. 2011 Jan 06; 6(1):e15868. PMID: 21253593; PMCID: PMC3017077.
    91. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone J, Stock PG. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010 Dec 27; 90(12):1595-601. PMID: 20978464; PMCID: PMC4296579.
    92. Melton AC, Bailey-Bucktrout SL, Travis MA, Fife BT, Bluestone J, Sheppard D. Expression of avß8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest. 2010 Dec; 120(12):4436-44. PMID: 21099117; PMCID: PMC2993595.
    93. Bluestone J, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol. 2010 Nov; 10(11):797-803. PMID: 20972473.
      View in: PubMed
    94. Sonn CH, Yu YB, Hong YJ, Shim YJ, Bluestone J, Min BH, Lee KM. Clusterin synergizes with IL-2 for the expansion and IFN-? production of natural killer cells. J Leukoc Biol. 2010 Nov; 88(5):955-63. PMID: 20729304.
      View in: PubMed
    95. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010 Aug 30; 207(9):1871-8. PMID: 20679400; PMCID: PMC2931175.
    96. Turka LA, Wood K, Bluestone J. Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr Opin Organ Transplant. 2010 Aug; 15(4):441-8. PMID: 20631613.
      View in: PubMed
    97. Kim TJ, Kim N, Kang HJ, Kim EO, Kim ST, Ahn HS, Bluestone J, Lee KM. FK506 causes cellular and functional defects in human natural killer cells. J Leukoc Biol. 2010 Dec; 88(6):1089-97. PMID: 20671192.
      View in: PubMed
    98. Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone J. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One. 2010 Jul 22; 5(7):e11726. PMID: 20668510; PMCID: PMC2908680.
    99. Jeker LT, Bluestone J. Small RNA regulators of T cell-mediated autoimmunity. J Clin Immunol. 2010 May; 30(3):347-57. PMID: 20393792.
      View in: PubMed
    100. Bluestone J, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010 Apr 29; 464(7293):1293-300. PMID: 20432533; PMCID: PMC4959889.
    101. Kim TJ, Kim N, Kim EO, Choi JR, Bluestone J, Lee KM. Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor. Immunology. 2010 Aug; 130(4):545-55. PMID: 20406306; PMCID: PMC2913265.
    102. Penaranda C, Tang Q, Ruddle NH, Bluestone J. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes. 2010 Jun; 59(6):1461-8. PMID: 20299465; PMCID: PMC2874707.
    103. Bluestone J, Krensky AM, Turka LA, Rotrosen D, Matthews JB. Ten years of the Immune Tolerance Network: an integrated clinical research organization. Sci Transl Med. 2010 Feb 17; 2(19):19cm7. PMID: 20371484.
      View in: PubMed
    104. Brusko TM, Bluestone J. Regulatory T cells directed to the site of the action. Proc Natl Acad Sci U S A. 2009 Dec 08; 106(49):20553-4. PMID: 19955436.
      View in: PubMed
    105. Bluestone J, Kuchroo V. Autoimmunity. Curr Opin Immunol. 2009 Dec; 21(6):579-81. PMID: 19879742; PMCID: PMC2788101.
    106. Penaranda C, Bluestone J. Is antigen specificity of autoreactive T cells the key to islet entry? Immunity. 2009 Oct 16; 31(4):534-6. PMID: 19833083.
      View in: PubMed
    107. Bluestone J, Mackay CR, O'Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nat Rev Immunol. 2009 11; 9(11):811-6. PMID: 19809471.
      View in: PubMed
    108. Bour-Jordan H, Bluestone J. How suppressor cells led to anergy, costimulation, and beyond. J Immunol. 2009 Oct 01; 183(7):4147-9. PMID: 19767564.
      View in: PubMed
    109. Esensten JH, Wofsy D, Bluestone J. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009 Oct; 5(10):560-5. PMID: 19798031; PMCID: PMC3086064.
    110. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone J. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009 Nov; 10(11):1185-92. PMID: 19783989; PMCID: PMC2778301.
    111. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone J. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009 Sep; 10(9):1000-7. PMID: 19633673; PMCID: PMC2729804.
    112. Norquay LD, D'Aquino KE, Opare-Addo LM, Kuznetsova A, Haas M, Bluestone J, White MF. Insulin receptor substrate-2 in beta-cells decreases diabetes in nonobese diabetic mice. Endocrinology. 2009 Oct; 150(10):4531-40. PMID: 19574401; PMCID: PMC2754683.
    113. Perruche S, Zhang P, Maruyama T, Bluestone J, Saas P, Chen W. Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome. J Immunol. 2009 Jul 15; 183(2):953-61. PMID: 19561097.
      View in: PubMed
    114. Esensten JH, Lee MR, Glimcher LH, Bluestone J. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol. 2009 Jul 01; 183(1):75-82. PMID: 19535634; PMCID: PMC2732575.
    115. Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, Mellor A, Bluestone J, Moser M. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut. 2009 Oct; 58(10):1363-73. PMID: 19505881; PMCID: PMC2917097.
    116. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone J. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol. 2009 Jun; 21(3):281-5. PMID: 19500966; PMCID: PMC2733784.
    117. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone J. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009 Aug; 132(2):166-73. PMID: 19443276; PMCID: PMC2735402.
    118. Bour-Jordan H, Bluestone J. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev. 2009 May; 229(1):41-66. PMID: 19426214; PMCID: PMC2714548.
    119. Louvet C, Kabre BG, Davini DW, Martinier N, Su MA, DeVoss JJ, Rosenthal WL, Anderson MS, Bour-Jordan H, Bluestone J. A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J Exp Med. 2009 Mar 16; 206(3):507-14. PMID: 19221395; PMCID: PMC2699118.
    120. Su MA, Stenerson M, Liu W, Putnam A, Conte F, Bluestone J, Anderson MS. The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patients. Clin Immunol. 2009 Apr; 131(1):139-44. PMID: 19150256; PMCID: PMC2949956.
    121. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone J. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009 Mar; 58(3):652-62. PMID: 19074986; PMCID: PMC2646064.
    122. You S, Alyanakian MA, Segovia B, Damotte D, Bluestone J, Bach JF, Chatenoud L. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann N Y Acad Sci. 2008 Dec; 1150:300-10. PMID: 19120317; PMCID: PMC3087168.
    123. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone J. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008 Dec 02; 105(48):18895-900. PMID: 19015530.
      View in: PubMed
    124. Bluestone J, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008 Oct; 8(10):2086-96. PMID: 18828769; PMCID: PMC3087374.
    125. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone J, Gordon JI, Chervonsky AV. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008 Oct 23; 455(7216):1109-13. PMID: 18806780; PMCID: PMC2574766.
    126. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone J. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med. 2008 Sep 01; 205(9):1983-91. PMID: 18725525; PMCID: PMC2526194.
    127. Bluestone J, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol. 2008 Nov; 28(6):677-84. PMID: 18716861.
      View in: PubMed
    128. Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes. 2008 Nov; 57(11):3013-24. PMID: 18689692; PMCID: PMC2570398.
    129. Fife BT, Bluestone J. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008 Aug; 224:166-82. PMID: 18759926.
      View in: PubMed
    130. Meagher C, Tang Q, Fife BT, Bour-Jordan H, Wu J, Pardoux C, Bi M, Melli K, Bluestone J. Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol. 2008 Jun 15; 180(12):7793-803. PMID: 18523243; PMCID: PMC2429990.
    131. Brusko TM, Putnam AL, Bluestone J. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev. 2008 Jun; 223:371-90. PMID: 18613848.
      View in: PubMed
    132. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone J. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008 May; 28(5):687-97. PMID: 18468463; PMCID: PMC2394854.
    133. Perruche S, Zhang P, Liu Y, Saas P, Bluestone J, Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med. 2008 May; 14(5):528-35. PMID: 18438416.
      View in: PubMed
    134. Brusko T, Bluestone J. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur J Immunol. 2008 Apr; 38(4):931-4. PMID: 18395864.
      View in: PubMed
    135. Tang Q, Bluestone J. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008 Mar; 9(3):239-44. PMID: 18285775; PMCID: PMC3075612.
    136. Bluestone J, Hebrok M. Safer, longer-lasting regulatory T cells with beta-catenin. Nat Med. 2008 Feb; 14(2):118-9. PMID: 18256611.
      View in: PubMed
    137. Cano DA, Rulifson IC, Heiser PW, Swigart LB, Pelengaris S, German M, Evan GI, Bluestone J, Hebrok M. Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes. 2008 Apr; 57(4):958-66. PMID: 18083786.
      View in: PubMed
    138. Bour-Jordan H, Bluestone J. B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest. 2007 Dec; 117(12):3642-5. PMID: 18060022; PMCID: PMC2096437.
    139. Szot GL, Koudria P, Bluestone J. Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp. 2007; (9):404. PMID: 18989445; PMCID: PMC2566322.
    140. Szot GL, Koudria P, Bluestone J. Murine pancreatic islet isolation. J Vis Exp. 2007; (7):255. PMID: 18989427; PMCID: PMC2565847.
    141. Bluestone J. Regulatory T cells: therapeutic potential for treating transplant rejection and type I diabetes. J Vis Exp. 2007; (7):257. PMID: 18989429; PMCID: PMC2565852.
    142. Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, Wang Y, Bernstein X, Huang X, Reichardt LF, Bluestone J, Sheppard D. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature. 2007 Sep 20; 449(7160):361-5. PMID: 17694047; PMCID: PMC2670239.
    143. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone J, Brillantes AM, Herold KC. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology. 2007 Nov; 148(11):5136-44. PMID: 17673522.
      View in: PubMed
    144. Bluestone J, Thomson AW, Shevach EM, Weiner HL. What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol. 2007 08; 7(8):650-4. PMID: 17653127.
      View in: PubMed
    145. Chatenoud L, Bluestone J. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol. 2007 Aug; 7(8):622-32. PMID: 17641665.
      View in: PubMed
    146. Bour-Jordan H, Salomon BL, Thompson HL, Santos R, Abbas AK, Bluestone J. Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol. 2007 Jul 15; 179(2):1004-12. PMID: 17617592.
      View in: PubMed
    147. Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone J, Sayegh MH. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol. 2007 Oct; 125(1):16-25. PMID: 17627890.
      View in: PubMed
    148. Chikuma S, Bluestone J. Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease. Eur J Immunol. 2007 May; 37(5):1285-9. PMID: 17429849.
      View in: PubMed
    149. You S, Leforban B, Garcia C, Bach JF, Bluestone J, Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A. 2007 Apr 10; 104(15):6335-40. PMID: 17389382; PMCID: PMC1851030.
    150. St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, Bluestone J. New reagents on the horizon for immune tolerance. Annu Rev Med. 2007; 58:329-46. PMID: 16987079.
      View in: PubMed
    151. Bour-Jordan H, Bluestone J. Sensory neurons link the nervous system and autoimmune diabetes. Cell. 2006 Dec 15; 127(6):1097-9. PMID: 17174888.
      View in: PubMed
    152. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone J. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med. 2006 Nov 27; 203(12):2737-47. PMID: 17116737; PMCID: PMC2118162.
    153. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28; 355(13):1318-30. PMID: 17005949.
      View in: PubMed
    154. Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone J, Herold KC. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes. 2006 Sep; 55(9):2588-94. PMID: 16936208.
      View in: PubMed
    155. Scalapino KJ, Tang Q, Bluestone J, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006 Aug 01; 177(3):1451-9. PMID: 16849451.
      View in: PubMed
    156. Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone J. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest. 2006 Aug; 116(8):2252-61. PMID: 16886063; PMCID: PMC1523399.
    157. Tang Q, Bluestone J. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev. 2006 Aug; 212:217-37. PMID: 16903917.
      View in: PubMed
    158. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone J. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006 Jul 10; 203(7):1701-11. PMID: 16818678; PMCID: PMC2118339.
    159. Tang Q, Bluestone J. Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? Nat Immunol. 2006 Jun; 7(6):551-3. PMID: 16715063.
      View in: PubMed
    160. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone J, Herold KC, von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest. 2006 May; 116(5):1371-81. PMID: 16628253; PMCID: PMC1440705.
    161. Bluestone J, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006 Mar; 24(3):233-8. PMID: 16546089.
      View in: PubMed
    162. Masteller EL, Tang Q, Bluestone J. Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol. 2006 Apr; 18(2):103-10. PMID: 16458533.
      View in: PubMed
    163. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone J. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol. 2006 Jan; 7(1):83-92. PMID: 16311599; PMCID: PMC3057888.
    164. Knoechel B, Lohr J, Kahn E, Bluestone J, Abbas AK. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med. 2005 Nov 21; 202(10):1375-86. PMID: 16287710; PMCID: PMC2212975.
    165. Bour-Jordan H, Thompson HL, Bluestone J. Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J Immunol. 2005 Nov 01; 175(9):5649-55. PMID: 16237054.
      View in: PubMed
    166. Bluestone J, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol. 2005 Dec; 17(6):638-42. PMID: 16209918.
      View in: PubMed
    167. Bisikirska B, Colgan J, Luban J, Bluestone J, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct; 115(10):2904-13. PMID: 16167085; PMCID: PMC1201661.
    168. Dai YD, Jensen KP, Lehuen A, Masteller EL, Bluestone J, Wilson DB, Sercarz EE. A peptide of glutamic acid decarboxylase 65 can recruit and expand a diabetogenic T cell clone, BDC2.5, in the pancreas. J Immunol. 2005 Sep 15; 175(6):3621-7. PMID: 16148106.
      View in: PubMed
    169. Chen W, Bluestone J, Herold KC. Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol. 2005 Sep-Dec; 24(5-6):287-305. PMID: 16318983.
      View in: PubMed
    170. Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone J. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol. 2005 Sep 01; 175(5):3053-9. PMID: 16116193.
      View in: PubMed
    171. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone J, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity. 2005 Aug; 23(2):115-26. PMID: 16111631.
      View in: PubMed
    172. Chikuma S, Abbas AK, Bluestone J. B7-independent inhibition of T cells by CTLA-4. J Immunol. 2005 Jul 01; 175(1):177-81. PMID: 15972645.
      View in: PubMed
    173. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone J. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun; 54(6):1763-9. PMID: 15919798.
      View in: PubMed
    174. Loser K, Scherer A, Krummen MB, Varga G, Higuchi T, Schwarz T, Sharpe AH, Grabbe S, Bluestone J, Beissert S. An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice. J Immunol. 2005 May 01; 174(9):5298-305. PMID: 15843526.
      View in: PubMed
    175. Kohm AP, Williams JS, Bickford AL, McMahon JS, Chatenoud L, Bach JF, Bluestone J, Miller SD. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol. 2005 Apr 15; 174(8):4525-34. PMID: 15814673.
      View in: PubMed
    176. Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone J, Thomas JW, Unutmaz D, Van Kaer L, Joyce S. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol. 2005 Apr 15; 174(8):4696-705. PMID: 15814694.
      View in: PubMed
    177. Bluestone J. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol. 2005 04; 5(4):343-9. PMID: 15775994.
      View in: PubMed
    178. Bluestone J. CTLA-4Ig is finally making it: a personal perspective. Am J Transplant. 2005 Mar; 5(3):423-4. PMID: 15707394.
      View in: PubMed
    179. Boehm BO, Bluestone J. Differential roles of costimulatory signaling pathways in type 1 diabetes mellitus. Rev Diabet Stud. 2004; 1(4):156-64. PMID: 17491700; PMCID: PMC1783691.
    180. Anderson MS, Bluestone J. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005; 23:447-85. PMID: 15771578.
      View in: PubMed
    181. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone J. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol. 2004 Nov; 34(11):2996-3005. PMID: 15468055.
      View in: PubMed
    182. Judkowski V, Rodriguez E, Pinilla C, Masteller E, Bluestone J, Sarvetnick N, Wilson DB. Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes. Clin Immunol. 2004 Oct; 113(1):29-37. PMID: 15380527.
      View in: PubMed
    183. Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone J. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest. 2004 Oct; 114(7):979-87. PMID: 15467837; PMCID: PMC518661.
    184. Bluestone J, Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A. 2004 Oct 05; 101 Suppl 2:14622-6. PMID: 15322272; PMCID: PMC521996.
    185. Eagar TN, Turley DM, Padilla J, Karandikar NJ, Tan L, Bluestone J, Miller SD. CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance. J Immunol. 2004 Jun 15; 172(12):7442-50. PMID: 15187122.
      View in: PubMed
    186. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone J. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004 Jun 07; 199(11):1455-65. PMID: 15184499; PMCID: PMC2211775.
    187. Robey EA, Bluestone J. Notch signaling in lymphocyte development and function. Curr Opin Immunol. 2004 Jun; 16(3):360-6. PMID: 15134786.
      View in: PubMed
    188. Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone J, Lanier LL. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity. 2004 Jun; 20(6):757-67. PMID: 15189740.
      View in: PubMed
    189. Eagar TN, Tang Q, Wolfe M, He Y, Pear WS, Bluestone J. Notch 1 signaling regulates peripheral T cell activation. Immunity. 2004 Apr; 20(4):407-15. PMID: 15084270.
      View in: PubMed
    190. Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone J. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant. 2004 Mar; 4(3):390-401. PMID: 14961992.
      View in: PubMed
    191. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. Insulin secretion in type 1 diabetes. Diabetes. 2004 Feb; 53(2):426-33. PMID: 14747294.
      View in: PubMed
    192. Jovasevic VM, Gorelik L, Bluestone J, Mokyr MB. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. J Immunol. 2004 Feb 01; 172(3):1449-54. PMID: 14734721.
      View in: PubMed
    193. Stock PG, Bluestone J. Beta-cell replacement for type I diabetes. Annu Rev Med. 2004; 55:133-56. PMID: 14746513.
      View in: PubMed
    194. Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone J. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol. 2003 Nov 15; 171(10):5587-95. PMID: 14607967.
      View in: PubMed
    195. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone J. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol. 2003 Oct 01; 171(7):3348-52. PMID: 14500627.
      View in: PubMed
    196. Belghith M, Bluestone J, Barriot S, Mégret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med. 2003 Sep; 9(9):1202-8. PMID: 12937416.
      View in: PubMed
    197. Park CG, Thiex NW, Lee KM, Szot GL, Bluestone J, Lee KD. Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution. Pharm Res. 2003 Aug; 20(8):1239-48. PMID: 12948022.
      View in: PubMed
    198. Matthews JB, Ramos E, Bluestone J. Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant. 2003 Jul; 3(7):794-803. PMID: 12814471.
      View in: PubMed
    199. Ding W, Beissert S, Deng L, Miranda E, Cassetty C, Seiffert K, Campton KL, Yan Z, Murphy GF, Bluestone J, Granstein RD. Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis. J Clin Invest. 2003 Jun; 111(12):1923-31. PMID: 12813028; PMCID: PMC161417.
    200. Bluestone J, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003 Mar; 3(3):253-7. PMID: 12658273.
      View in: PubMed
    201. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone J. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest. 2003 Feb; 111(3):409-18. PMID: 12569167; PMCID: PMC151852.
    202. Starwalt SE, Masteller EL, Bluestone J, Kranz DM. Directed evolution of a single-chain class II MHC product by yeast display. Protein Eng. 2003 Feb; 16(2):147-56. PMID: 12676983.
      View in: PubMed
    203. Tang Q, Smith JA, Szot GL, Zhou P, Alegre ML, Henriksen KJ, Thompson CB, Bluestone J. CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. J Immunol. 2003 Feb 01; 170(3):1510-6. PMID: 12538715.
      View in: PubMed
    204. Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone J. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat Immunol. 2003 Feb; 4(2):182-8. PMID: 12524538.
      View in: PubMed
    205. Chikuma S, Imboden JB, Bluestone J. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2003 Jan 06; 197(1):129-35. PMID: 12515820; PMCID: PMC2193802.
    206. Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone J, Lanier LL. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity. 2003 Jan; 18(1):41-51. PMID: 12530974.
      View in: PubMed
    207. Boden E, Tang Q, Bour-Jordan H, Bluestone J. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found Symp. 2003; 252:55-63; discussion 63-6, 106-14. PMID: 14609212.
      View in: PubMed
    208. Chikuma S, Bluestone J. CTLA-4 and tolerance: the biochemical point of view. Immunol Res. 2003; 28(3):241-53. PMID: 14713717.
      View in: PubMed
    209. Finger EB, Bluestone J. When ligand becomes receptor--tolerance via B7 signaling on DCs. Nat Immunol. 2002 Nov; 3(11):1056-7. PMID: 12407416.
      View in: PubMed
    210. Masteller EL, Bluestone J. Immunotherapy of insulin-dependent diabetes mellitus. Curr Opin Immunol. 2002 Oct; 14(5):652-9. PMID: 12183168.
      View in: PubMed
    211. Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone J, Clark MR. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002 Sep; 29(9):1907-13. PMID: 12233885.
      View in: PubMed
    212. Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone J, Alegre ML. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 2002 Jul 15; 169(2):633-7. PMID: 12097362.
      View in: PubMed
    213. Rotrosen D, Matthews JB, Bluestone J. The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol. 2002 Jul; 110(1):17-23. PMID: 12110811.
      View in: PubMed
    214. Rulifson IC, Szot GL, Palmer E, Bluestone J. Inability to induce tolerance through direct antigen presentation. Am J Transplant. 2002 Jul; 2(6):510-9. PMID: 12118894.
      View in: PubMed
    215. Chikuma S, Bluestone J. CTLA-4: acting at the synapse. Mol Interv. 2002 Jul; 2(4):205-8. PMID: 14993389.
      View in: PubMed
    216. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone J. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30; 346(22):1692-8. PMID: 12037148.
      View in: PubMed
    217. Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone J. The Src family kinase Fyn mediates signals induced by TCR antagonists. J Immunol. 2002 May 01; 168(9):4480-7. PMID: 11970992.
      View in: PubMed
    218. Eagar TN, Karandikar NJ, Bluestone J, Miller SD. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol. 2002 Apr; 32(4):972-81. PMID: 11920563.
      View in: PubMed